NRx Pharmaceuticals, Inc.
NRXP
$2.27
-$0.02-0.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -459.33% | 79.45% | -20.97% | -50.69% | 28.54% |
| Total Depreciation and Amortization | -50.00% | 100.00% | 0.00% | 0.00% | -50.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,917.86% | -131.83% | 301.93% | 144.35% | -287.57% |
| Change in Net Operating Assets | -300.00% | -98.59% | 33.23% | -5.57% | 198.28% |
| Cash from Operations | 9.02% | 9.99% | 30.21% | -15.01% | 30.06% |
| Capital Expenditure | -- | -- | -- | -- | 150.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 150.00% |
| Total Debt Issued | 40.70% | -- | -- | -- | -- |
| Total Debt Repaid | -42.78% | -264,300.00% | 99.95% | -69.29% | 52.36% |
| Issuance of Common Stock | -100.00% | -93.03% | 23.22% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -0.39% | -- | -- | -- | -- |
| Cash from Financing | -7.74% | -34.61% | 695.19% | 135.39% | 25.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.44% | -143.52% | 117.67% | 23.94% | 29.01% |